Business Wire

Intel 471 Releases Report to Help Europe’s Critical Entities Navigate the Network and Information Security Directive (NIS2)

5.11.2024 10:00:00 EET | Business Wire | Press release

Share

Today, Intel 471, a global leader in cyber threat intelligence (CTI) and intelligence-driven solutions, released its new report, NIS2 Operationalising Cyber Threat Intelligence for Critical Infrastructure Resiliency.The report offers key insights into how actionable CTI can help organisations navigate Europe’s new cybersecurity regulations, proactively mitigate digital risk, improve cyber resilience, and avoid penalties and fines.

National laws implementing the European Union’s NIS2 Directive (EU) 2022/2555 to lift the cyber resilience of critical infrastructure across Europe went into effect on 18 October 2024. NIS2 has dramatic implications for how important and essential operators of critical services manage cyber risks compared to its predecessor, NIS1, the 2016 Network and Information Systems Directive. It gives regulators wider supervisory powers, introduces higher standards for cyber risk management, mandatory incident reporting and tougher sanctions. If not followed, essential entities face administrative fines of up to €10 million, or 2% of annual global turnover, whichever is higher. This directive is a major shift in cyber risk management and supply chain security for entities operating energy, transport, banking, health, water, digital infrastructure, managed IT services, public administration and many more subsectors.

In this report, Intel 471 outlines how these entities in critical sectors affected by the European Commission’s NIS2 Directive can leverage premier CTI and intelligence-driven threat hunting to proactively mitigate digital threats and meet the directive’s higher risk management and incident reporting requirements. The report provides organizations with best practices to reduce cyber risk, anticipate threats, prioritise remediation of cloud resources and other IT assets, and continuously improve risk management measures to boost resilience and recovery.

“It is the right time to adopt NIS2 given today’s high stakes cybersecurity threat landscape. We’re seeing nation-state and cybercrime activity increasingly overlap, often driven by geopolitical events that create higher risks to all critical sectors in Europe. Defenders are overwhelmed by data and need timely intelligence that helps them focus on emerging threats, adversary tactics, and vulnerabilities that pose the greatest risk to them,” says Michael DeBolt, Chief Intelligence Officer at Intel 471. “Our unmatched human intelligence capability, patented malware emulation and tracking insights, and human-validated automated collection across thousands of threat actor communities help our customers in critical sectors across the globe understand their exposure and proactively mitigate digital risks. We go a step further by providing carefully curated intelligence-driven threat hunting content to rapidly identify and stop advanced threats in their tracks.”

Organisations impacted by NIS2 can utilise Intel 471’s unique CTI capabilities to improve security posture, reduce their attack surface and enhance resilience. “Being prepared with timely and trusted intelligence and threat hunting content that identifies adversarial techniques missed by traditional detection methods is critical for organisations to gain early visibility of emerging threats and proactively respond to cyber incidents. This intelligence-led approach to cyber defense and third party risk is at the heart of NIS2 directive,” says DeBolt.

NIS2’s broader scope than NIS1 dictates that many affected entities are urgently working to mature their CTI programs to better support their NIS2 cyber risk management strategies. The CTI Capability Maturity Model (CTI-CMM) — a free and vendor-neutral, “stakeholder-first” model, sponsored by Intel 471 and 27 other CTI industry expert peers from across the globe, assists organisations in building successful, impactful CTI programs.

For more details and to download the Intel 471 report, please visit: NIS2 Operationalising Cyber Threat Intelligence for Critical Infrastructure Resilience

About Intel 471

Intel 471 empowers enterprises, government agencies, and other organizations to win the cybersecurity war using the real-time insights about adversaries, their relationships, threat patterns, and imminent attacks relevant to their businesses. The company’s platform collects, interprets, structures, and validates human-led, automation-enhanced intelligence, which fuels our external attack surface and advanced behavioral threat hunting solutions. Customers utilize this operationalized intelligence to drive a proactive response to neutralize threats and mitigate risk. Organizations across the globe leverage Intel 471’s world-class intelligence, our trusted practitioner engagement and enablement, and globally dispersed ground expertise as their frontline guardian against the ever-evolving landscape of cyber threats to fight the adversary — and win. Learn more at www.intel471.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241105566758/en/

Contacts

Erica Stuchel
Intel471@w2comm.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 10:19:00 EEST | Press release

Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patients with unmet needs.” Pembrolizumab is a humanized monoclonal antibody that acts as an immune checkpoint inhibitor by targeting and blocking the programmed cell death protein 1 (PD-1) receptor on T cells. It is used to treat vari

IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 10:00:00 EEST | Press release

IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi

Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 10:00:00 EEST | Press release

Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European Medicines Agency (EMA) for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/DDC inhibitor-based treatment regimens. CHMP recommendation is based on data from the Phase 3 RISE-PD trial, which compared Hopledo® with immediate release levodopa/carbidopa (LD/CD) formulation in patients with Parkinson’s disease and moderate to severe motor fluctuations. In the study, Hopledo® demonstrated a significant increase in Good ON time over immediate release LD/CD with fewer daily doses and a comparable safety profile1. Hopledo® is a first-in-class, oral, modified-release formulation of LD/CD designed for the treatment of fluctuations of Parkinson’s diseas

Enhertu ® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 09:30:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across three phase 2 trials, including DESTINY-PanTumor02, DESTINY-Lung01 and DESTINY-CRC02. In DESTINY-PanTumor02, Enhertu demonstrated a confirmed objective response rate (ORR) of 52.3% (95% confidence interval [CI]: 42.6-6

Beerenberg Prevails in Patent Case Against Aspen Aerogels29.6.2026 08:00:00 EEST | Press release

The Korean Patent Court has invalidated three of Aspen Aerogels’ patents related to improved hydrophobic aerogel material. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260628192007/en/ Beerenberg delivers high-end insulation solutions built for performance, reliability, and long-term value. (Photo: Beerenberg) The ruling confirms the conclusion of the Intellectual Property Trial and Appeal Board (IPTAB) that the patents did not meet the necessary requirements for patentability. Beerenberg, which specializes in high-end insulation products, welcomes the court’s decision. “We are pleased that the case has now been concluded and that any uncertainty regarding the infringement claims has been removed,” says CEO Arild Apelthun. About Beerenberg Beerenberg has delivered cost-efficient solutions to a wide range of industrial enterprises for 49 years. The company is one of the leading suppliers of maintenance and modification serv

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye